Quick Heal Technologies Ltd
Un-audited Financial Results for the ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 30 Jul 2026, 10:03 PM IST · BSE ID: 103001cb-e51e-4ce6-a64b-62b424a32c9e
View Original BSE Filing (PDF)
💡
In Simple Terms
Quick Heal Technologies announced its quarterly financial results, reported a loss, and proposed re-appointing a director.
🤖 AI Summary
- Quick Heal Technologies reported unaudited consolidated Q1 FY27 revenue of ₹ 45.0 Cr and a Net Loss (PAT) of ₹ (5.3) Cr.
- Board proposed re-appointment of Mr. Richard Stiennon as Non-Executive Independent Director for a second 5-year term.
- Re-appointment of Mr. Richard Stiennon is effective from September 27, 2026, subject to shareholder approval at AGM.
- Company shifted its Registered Office and Books of Accounts location within Pune, effective July 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue Q1 FY27
₹ 45.0 Cr
-21.2%
EBITDA Q1 FY27
₹ (17.6) Cr
EBITDA Margin Q1 FY27
(39.1%)
PAT Margin Q1 FY27
(11.7%)
Revenue Q1 FY26
₹ 57.2 Cr
🏢 How This Affects the Company
The company’s cybersecurity solutions continue to face market headwinds in the consumer vertical, while enterprise segment shows customer wins in Defence, BFSI, and IT services.
Consolidated revenue decreased to ₹ 45.0 Cr in Q1 FY27 from ₹ 57.2 Cr in Q1 FY26. The company reported a Net Loss (PAT) of ₹ (5.3) Cr.
The Registered Office and the location for keeping Books of Accounts have been relocated within Pune, effective July 30, 2026.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to approve the re-appointment of Mr. Richard Stiennon as Non-Executive Independent Director at the ensuing Annual General Meeting.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and corporate governance decisions, including director appointments requiring their approval.
🔍
Management Signal
The management's proposal for re-appointing Mr. Richard Stiennon signals a desire for continuity in independent board oversight.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder approval of Mr. Richard Stiennon's re-appointment at the upcoming AGM.
Q2 FY27 financial results to assess revenue and profitability trends.
Updates on new offerings and enterprise segment growth initiatives.
MEDIUM RISK
Continued decline in revenue and net losses indicate operational challenges, particularly in the consumer segment.
💡 Investor Takeaway
Quick Heal Technologies reported consolidated Q1 FY27 revenue of ₹ 45.0 Cr, down from ₹ 57.2 Cr in Q1 FY26. The company recorded a Net Loss (PAT) of ₹ (5.3) Cr. The Board has proposed Mr. Richard Stiennon's re-appointment as an Independent Director.
⚖️ Strengths & Concerns
✅ Positives
- Secured a multi-year order to protect 1.5 lakh devices from the Defence sector, indicating continued enterprise traction.
- Added a significant Seqrite XDR customer in the banking technology sector, reinforcing presence in critical industries.
⚠️ Concerns
- Consolidated revenue declined to ₹ 45.0 Cr in Q1 FY27 from ₹ 57.2 Cr in Q1 FY26, showing a decrease.
- Reported a Net Loss (PAT) of ₹ (5.3) Cr in Q1 FY27, with PAT Margin at (11.7)%, indicating continued unprofitability.
❓ Frequently Asked Questions
What was Quick Heal Technologies' consolidated revenue for Q1 FY27?
Quick Heal Technologies reported a consolidated revenue of ₹ 45.0 Cr for the quarter ended June 30, 2026 (Q1 FY27).
What was the Net Loss (PAT) for Quick Heal Technologies in Q1 FY27?
The Net Loss (PAT) for Quick Heal Technologies in Q1 FY27 was ₹ (5.3) Cr, with a PAT Margin of (11.7%).
Who is being proposed for re-appointment as an Independent Director at Quick Heal Technologies?
Mr. Richard Stiennon (DIN: 09324046) has been proposed for re-appointment as a Non-Executive Independent Director for a second term of 5 consecutive years.
When is the re-appointment of Mr. Richard Stiennon effective?
The re-appointment of Mr. Richard Stiennon is proposed to be effective from September 27, 2026, until September 26, 2031, subject to shareholder approval.
Questions based on this BSE filing only. For information purposes.